FDA approves NeuViz Prime 128-slice CT scanner.- Neusoft Medical.
Neusoft Medical Systems USA announced the FDA market clearance and availability of a new 128-slice CT scanner. The latest advance in more than 20 years of continual CT innovation. The NeuViz Prime 128-slice CT scanner offers attractive diagnostic images enhanced by several key features.
First, the system has Spectral Imaging capabilities The ability to perform image acquisition and processing at multiple energy levels is improving visualization for computed tomography and enhancing patient care. Spectral imaging is field upgradable for the NeuViz Prime. Secondly, the NeuViz Prime offers 0.259 second rotation speed, a critical feature for any application requiring high temporal resolution. The subsequent motion suppression improves imaging in trauma, pediatrics, and cardiac cases. Lastly, a new X-Ray tube with a liquid bearing design improves heat storage and dissipation. With the new tube, heat is removed faster than it is introduced, eliminating scanning delays. The tube also allows 60 kV imaging at the maximum tube current of 833 mA. 60 kV imaging is ideal for pediatric studies.
The NeuViz Prime is the latest addition to the NeuViz family of CT scanners sold in the US including the NeuViz 64In/En, and NeuViz 16. Each Neusoft CT system comes with a feature-rich configuration, eliminating expensive upgrades and is supported by an industry leading warranty package for exceptional technical support.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.